Australian collaborative trial of antenatal thyrotropin-releasing hormone (ACTOBAT) for prevention of neonatal respiratory disease
References (24)
- et al.
Respiratory disease in very-low-birthweight infants after prenatal thyrotropin-releasing hormone and glucocorticoid
Lancet
(1992) - et al.
A randomised controlled trial of antepartum thyrotropin-releasing hormone and betamethasone in the prevention of respiratory disease in preterm infants
Am J Obstet Gynecol
(1994) - et al.
Synergistic hormonal effects on lung maturation in fetal sheep
J Appl Physiol
(1988) - et al.
Synergism of cortisol and thyrotropin releasing hormone in lung maturation in fetal sheep
J Appl Physiol
(1988) - et al.
Fetal lung maturation: the combined use of corticosteroids and thyrotropin-releasing hormone
Obstet Gynecol
(1989) - et al.
Maternal administration of thyrotropin-releasing hormone for prevention of neonatal respiratory distress syndrome
Proceedings of 6th Congress of the Federation of the Asia-Oceania Perinatal Societies.
(1990) - et al.
Controlled trial of prenatal betamethasone plus TRH vs betamethasone plus placebo for prevention of RDS in preterm infants
Pediatr Res
(1992) - et al.
Controlled trial of prenatal betamethasone (B) plus TRH for prevention of respiratory distress syndrome (RDS) in preterm infants
Pediatr Res
(1992) - et al.
Thyroid-stimulating hormone response to synthetic thyrotropin-releasing hormone in man
BMJ
(1976)
Response to thyrotropin-releasing hormone (TRH) in normal man
J Clin Endocrinol Metab
Cited by (88)
OGT-related mitochondrial motility is associated with sex differences and exercise effects in depression induced by prenatal exposure to glucocorticoids
2018, Journal of Affective DisordersCitation Excerpt :Glucocorticoids (GCs) are known to treat preterm delivery in pregnant women (ACTOBAT Study Group, 1995); however, prenatal exposure to GCs has been found to trigger abnormal behaviors and deleterious neurological effects on offspring both in animals and in humans (Braithwaite et al., 2015; Kim et al., 2015).
Trials with Thyroid Hormone in Preterm Infants: Clinical and Neurodevelopmental Effects
2008, Seminars in PerinatologyCitation Excerpt :Also, because amniotic administration is an invasive procedure, while maternal administration of glucocorticoids is a proven and effective therapy to induce lung maturation, investigations might not have been stimulated to set up these trials. A combination therapy of maternal administration of thyrotropin-releasing hormone and glucocorticoids was not found to be effective in improving respiratory outcomes of premature infants.31 Thyroid hormones increase cardiac inotropy and chronotropy.13,32
Respiratory Disorders of the Newborn
2008, Pediatric Respiratory MedicineWhat is the Evidence for Drug Therapy in the Prevention and Management of Bronchopulmonary Dysplasia?
2008, The Newborn Lung: Neonatology Questions and ControversiesAntenatal magnesium sulphate neuroprotection in the preterm infant
2007, Seminars in Fetal and Neonatal MedicineCitation Excerpt :Several recent randomised controlled trials (RCTs) of different therapies, launched because of promising data from animal studies or earlier smaller human studies, have proved to be unsuccessful at improving long-term outcomes for very preterm infants. One example is antenatal thyrotropin-releasing hormone (TRH), which not only failed to reduce the rate of respiratory distress when it was expected to do so,13 but was also associated with adverse longer-term outcomes in the babies exposed to TRH in the uterus.14 Another example is prophylactic indometacin, which reduced the rate of major intraventricular haemorrhage in an earlier smaller study15 but did not improve long-term outcome in a much larger RCT.16
Neonatal respiratory distress syndrome after repeat exposure to antenatal corticosteroids: a randomised controlled trial
2006, LancetCitation Excerpt :This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN48656428. A sample size of 980 women was needed to detect a 25% reduction in the risk of respiratory distress syndrome (the main endpoint of the trial) from 30%20 to 22·5% with 80% power (β=0·20) at a two-sided significance level of 5% (α=0·05). Data were reviewed twice by the independent data monitoring committee who were not aware of treatment-group allocation.
- 1
ACTOBAT participants listed at end of paper